-324. 15. World Health Organization. Collaborating Centre for Drug Statistics and Methodology. ATC Index with DDDs. ATC/DDD Index 2010. https://www.whocc.no/atc_ddd_index/ 16. Fedeli LG, Vidigal PG, Leite CM, et al. Logistics of collection and transportation of biological samples and the organization of the central laboratory in the ELSA-Brasil. Rev Sa e P l. 2013;47(Suppl 2):63-71. 17. Alwhaibi M, Balkhi B, Alhawassi TM, et al. Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018;8:e020852. 18. Conjugated Antibodies , Kjome RLS, S vik U et al. The potential for deprescribing in care home residentes with Type 2 diabetes. Int J Clin Pharmacol. 2016;38(4):977-984. 19. Carvalho MFC, Romano-Lieber NS, Bergsten-Mendes G, et al. Polifarm ia entre idosos do munic io de S o Paulo-Estudo SABE. a Rev Bras Epidemiol. 2012;15:817-827. 20. Formiga F, Vidal X, AgustA, et al. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet Med. 2016;33(5): 655-662. 21. Micromedex Drug Ref internet dabatase. https://www.ibm.com/ watson-health/about/micromedex. Accessed 10 June 2020 22. World Health Organization. Global strategy on diet, physical activity and health. 2004. https://www.who.int/dietphysicalactivity/strategy/ eb11344/strategy_english_web.pdf Accessed 10 June 2020 23. Nunes MA, Alves MGM, Chor D, Schmidt MI, Duncan BB. Adapta o a transcultural do CIS-R (Clinical Interview Schedule - Revised Version) para o portugu no estudo longitudinal de sa e do adulto (ELSA). Rev HCPA. 2011;31(4):487-490. 24. de Brito GM, Gianella D, Faria M, et al. Carrier Free Antibodies of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil. Rev Diabet Stud. 2006;3:82-87. 25. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-453. 26. Schroeder EB, Hanratty R, Beaty BL, Bayliss EA, Havranek EP, Steiner JF. Simultaneous control of diabetes mellitus, hypertension, and hyperlipidemia in 2 health systems. Circ Cardiovasc Qual Outcomes. 2012;5(5):645-653. 27. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140-149. 28. Adhikari S, Shrestha S, Shakya R, et al. Prevalance of chronic complications and drug utilization pattern of type II diabetes mellitus. Mathews J Diabetes Obes. 2017;2:01-08. 29. Mendes ABV, Fittipaldi JAS, Neves RCS, Chacra AR, Moreira ED Jr. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta Diabetol. 2010;47:137-145. 30. Rossaneis MA, Andrade SM, Gvozd R, et al. Factors associated with glycemic control in people with diabetes mellitus. Ci Saude Colet. 2019;24(3):997-1005. 31. Viana LV, Leit o CB, Kramer CK, et al. Poor glycaemic control in Braa zilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study. BMJ Open. 2013;3(9):e003336.COUTINHO ET AL.32. Lima RF, Fontbonne A, Carvalho EM, et al. Factors associated with glycemic control in people with diabetes at the Family Health Strategy in Pernambuco. Rev Esc Enferm USP. 2016;50(6):937-945. 33. Breuker C, Abr.